![bill_anderson](https://pharmafile.com/wp-content/uploads/2016/12/bill_anderson.jpg)
Genentech announces Bill Anderson as new CEO
pharmafile | December 16, 2016 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Bill Anderson, Genentech, Roche
Genentech, the biotech subsidiary of Roche, has announced that Genentech veteran, Ian Clark, will retire as CEO on 1 January. Ian Clark performed his role as the CEO of Genentech for the last 15 years, bringing through 15 new drugs in the process and dealing with the after-effects of Roche’s buyout of the company.
Bill Anderson takes the positon of CEO after having worked within Genentech for the last decade. He has held a number of positions within the company and will switch to the role from his current position as North American commercial chief, a position he has held since July. Prior to this, he held the position of global product strategy chief for Roche and headed Genentech’s bio-oncology business.
“Bill is an outstanding leader with a deep understanding of the company and proven expertise in bringing important medicines to people with serious diseases,” said Daniel O’Day, CEO of Roche’s pharmaceuticals division.
Related Content
![](https://pharmafile.com/wp-content/uploads/2023/05/national-cancer-institute-XknuBmnjbKg-unsplash-300x200.jpg)
FDA approves Roche’s HPV self-collection screening option
Roche has announced that the US Food and Drug Administration (FDA) has approved its human …
![](https://pharmafile.com/wp-content/uploads/2023/09/robina-weermeijer-Pw9aFhc92P8-unsplash-3-300x169.jpg)
Roche’s Alecensa approved by FDA as lung cancer treatment
Roche has announced that the US Food and Drug Administration (FDA) has approved Alecensa (alectinib) …
![](https://pharmafile.com/wp-content/uploads/2023/10/shutterstock_1918452782-3-300x148.jpg)
Genentech’s Columbi meets primary endpoint in phase 3 trial for lymphoma treatment
Genentech, part of the Roche Group, has announced that its phase 3 STARGLO trial has …